We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Definiens Releases TissueMap 2.0 for Advanced Oncology Research
Product News

Definiens Releases TissueMap 2.0 for Advanced Oncology Research

Definiens Releases TissueMap 2.0 for Advanced Oncology Research
Product News

Definiens Releases TissueMap 2.0 for Advanced Oncology Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Definiens Releases TissueMap 2.0 for Advanced Oncology Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Definiens has unveiled the release of Definiens TissueMap 2.0, highlighting the company’s focus on oncology research. The image analysis software application is especially designed for the detailed, automated morphometric quantification of biomarkers of nuclei or cell bodies in epithelial tumors or xenografts.

The application features the detection of viable and necrotic tissue in xenografts, as well as regions of IHC (DAB) positively stained nuclei or cells in the viable tissue. This enables pathologists to automate the process of complex or highly apoptotic xenograft analysis in oncology research.

The discovery and application of oncology biomarkers have enhanced opportunities for individual disease treatment by identifying new drug targets. They therefore have a significant impact on the entire process of drug development including the emergence and growth of imaging technologies utilized to acquire accurate measurements of disease parameters. The use of imaging technologies, such as Definiens TissueMap 2.0, improves the selection and prioritization of quality candidates early in the drug development pipeline.

Definiens TissueMap 2.0 identifies areas and structures of interest in image data allowing researchers to distinguish between viable and necrotic tumor areas and to quantify markers. It offers:

• Full tissue slide analysis

• Reproducible results

• Platform independence and connectivity

• Easy customization

• Measurement of morphological parameters

Definiens TissueMap 2.0 encompasses the assessment of any biomarkers targeting an antigen located in the nucleus such as proliferation markers (Ki67, PCNA, BrdU, etc.), apoptosis markers such as Cap3 as well as estrogen or progesterone receptors. Antibodies or markers co-/located in the cell body, such as cytokeratines (CD31, AE1/3, etc.) and other proteins (CD45, CD23 or similar) can also be evaluated.

Definiens TissueMap 2.0 enables the quantification of biomarker expression patterns in image data regardless of staining methodology. The software application effectively analyzes image data in oncology research, including cases involving poor staining technique and data obtained from heterogeneous equipment. It also enables the automated detection of relevant morphological structure in tissue and tumor sections.

Advertisement